Condensed Consolidated Statements of Operations (USD $) In Thousands, except Share data	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Net sales	$ 144,747	$ 138,906	$ 427,462	$ 420,573
Cost of sales	36,029	32,266	104,082	99,046
Gross profit	108,718	106,640	323,380	321,527
Operating expenses
Sales and marketing	57,615	57,281	171,412	170,756
General and administrative	20,214	21,568	67,123	63,410
Research and development	6,555	7,375	19,373	23,272
Amortization of intangible assets	1,319	1,402	3,947	4,259
Net gain on sale of vascular operations		20		(12,319)
Charges related to U.S. Government inquiries (Note 17)			46,000
Operating Expenses, Total	85,703	87,646	307,855	249,378
Operating income	23,015	18,994	15,525	72,149
Other income (expense)
Interest expense, net	(2,267)	(3,481)	(6,881)	(14,772)
Loss on refinancing of credit facility		(550)		(550)
Gain on interest rate swap				1,254
Other expense	(368)	(674)	(1,753)	(904)
Nonoperating Income (Expense), Total	(2,635)	(4,705)	(8,634)	(14,972)
Income before income taxes	20,380	14,289	6,891	57,177
Income tax expense	(8,002)	(5,769)	(20,356)	(20,933)
Net income (loss)	$ 12,378	$ 8,520	$ (13,465)	$ 36,244
Net income (loss) per common share:
Basic	$ 0.67	$ 0.48	$ (0.74)	$ 2.06
Diluted	$ 0.66	$ 0.48	$ (0.74)	$ 2.03
Weighted average number of common shares:
Basic	18,384,451	17,626,319	18,146,076	17,565,414
Diluted	18,850,625	17,836,537	18,146,076	17,824,273